First-ever company developing bioabsorbable heart valves and vessels to allow Endogenous Tissue Restoration in patients with heart conditions
Zurich, Switzerland, 14 October 2015 — Xeltis has been named as one of the 15 most promising private medtech companies in the industry globally, as part of annual Fierce 15 list issued today. The list is compiled each year by FierceMedicalDevices, an internationally recognised authoritative daily report in medical technology.
Swiss-Dutch Xeltis is the first-ever medical device company developing bioabsorbable heart valves and vessels. The Xeltis novel technology is designed to allow a new therapeutic approach called Endogenous Tissue Restoration (ETR), potentially a complete paradigm shift in cardiovascular treatment.
The Xeltis products are made of bioabsorbable polymers structured as a porous matrix, which is designed to work as a valve or vessel once implanted, and to allow the body’s
natural healing process to pervade it with new functioning tissue. As the natural heart valve or vessel forms, the matrix is structured to be bioabsorbed and leave the patient with its own healthy tissue.
“Today’s recognition acknowledges the extraordinary potential of our innovative technology – stated Laurent Grandidier, CEO at Xeltis – ‘and it is an important credit for a company whose products are still in development and a few years away from the market”.
ETR has the potential to help reduce the risk of patient complications generally caused by foreign material in the body, as well as the risk of repeated procedures normally needed for patients with existing replacement valves, therefore possibly lowering the overall healthcare costs.
“Xeltis is dedicated to transforming the standard of care in cardiovascular treatment – added Grandidier – our ambition is offering patients that need heart valve or vessel replacement new hope for better and longer lives”.
About the Xeltis technology and ETR
The Xeltis technology is based on Nobel prize-winning science of supramolecular chemistry by professor Jean-Marie Lehn. It stems from world-leading work in chemistry of materials, biomechanics and microstructure from the Eindhoven University of Technology, The Netherlands – a European center of excellence for technology and open innovation.
The Xeltis technological platform can be applied to a number of heart valves and vessels, providing the company’s pipeline with extraordinary potential in cardiovascular treatment. The first product Xeltis is planning to bring to market in a few years is a pulmonary valve for pediatric patients.
There are around 80,000 children born each year with congenital heart defects requiring right ventricular outflow tract (RVOT) reconstruction, a procedure that involves pulmonary valve replacement. With a long-life span ahead of them, young patients would benefit even more than adult patients from reduced risk of repeated surgeries. Xeltis has already secured positive data on ETR from its first clinical trial in patients born with only one functioning heart ventricle requiring the implantation of a heart conduit.